Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEANASDAQ:CLSNNASDAQ:IMMXNASDAQ:IMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.44-3.4%$1.81$1.29▼$13.07$54.10M-0.07905,179 shs542,981 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsIMMXImmix Biopharma$2.33+3.6%$1.85$1.26▼$2.71$64.95M0.27145,185 shs302,264 shsIMRXImmuneering$1.68-1.2%$1.40$1.00▼$3.83$60.46M-0.222.34 million shs130,357 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion+7.19%+2.76%-32.27%-48.44%-86.32%CLSNImunon0.00%0.00%0.00%0.00%0.00%IMMXImmix Biopharma+15.38%-6.64%+11.39%+26.40%+3.21%IMRXImmuneering-5.83%+16.90%+15.31%+2.73%+16.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMEABiomea Fusion2.808 of 5 stars3.50.00.00.03.43.31.3CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AIMMXImmix Biopharma2.6891 of 5 stars3.54.00.00.01.91.70.6IMRXImmuneering3.6892 of 5 stars3.35.00.00.02.83.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 3.09Buy$22.601,469.44% UpsideCLSNImunon 0.00N/AN/AN/AIMMXImmix Biopharma 3.00Buy$7.00200.43% UpsideIMRXImmuneering 2.50Moderate Buy$15.33812.70% UpsideCurrent Analyst Ratings BreakdownLatest CLSN, BMEA, IMMX, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/7/2025IMRXImmuneeringOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.005/6/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/6/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/10/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/2/2025BMEABiomea FusionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$11.00 ➝ $3.003/31/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/24/2025BMEABiomea FusionOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.003/24/2025BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/24/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$4.74 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00IMMXImmix BiopharmaN/AN/AN/AN/A$0.81 per shareN/AIMRXImmuneering$320K188.93N/AN/A$3.09 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$117.25M-$3.55N/AN/AN/AN/A-118.90%-93.66%7/30/2025 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AIMMXImmix Biopharma-$15.43M-$0.70N/AN/AN/AN/A-102.68%-80.89%8/11/2025 (Estimated)IMRXImmuneering-$53.47M-$1.96N/AN/AN/AN/A-79.19%-69.08%8/5/2025 (Estimated)Latest CLSN, BMEA, IMMX, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025BMEABiomea Fusion-$0.84-$0.80+$0.04-$0.80N/AN/A5/5/2025Q1 2025IMRXImmuneering-$0.41-$0.42-$0.01-$0.42N/AN/A3/31/2025Q4 2024BMEABiomea Fusion-$1.00-$0.81+$0.19-$0.81N/AN/A3/24/2025Q4 2024IMMXImmix Biopharma-$0.25-$0.16+$0.09-$0.16N/AN/A3/20/2025Q4 2024IMRXImmuneering-$0.42-$0.58-$0.16-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A3.393.39CLSNImunon0.136.526.52IMMXImmix BiopharmaN/A3.473.47IMRXImmuneeringN/A7.997.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%CLSNImunon12.97%IMMXImmix Biopharma11.26%IMRXImmuneering67.65%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion27.57%CLSNImunon4.66%IMMXImmix Biopharma55.40%IMRXImmuneering25.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5037.57 million26.25 millionOptionableCLSNImunon277.10 million6.77 millionOptionableIMMXImmix Biopharma927.88 million14.06 millionOptionableIMRXImmuneering6035.99 million23.29 millionNot OptionableCLSN, BMEA, IMMX, and IMRX HeadlinesRecent News About These CompaniesImmuneering to Present at the Jefferies Global Healthcare ConferenceMay 29 at 8:00 AM | globenewswire.comImmuneering Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 5, 2025 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Short Interest UpdateMay 2, 2025 | marketbeat.comImmuneering (IMRX) Expected to Announce Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comImmuneering to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | globenewswire.comImmuneering Corporation: Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 21, 2025 | finanznachrichten.deImmuneering Corporation Announces Grant of Inducement AwardMarch 21, 2025 | globenewswire.comImmuneering Corporation: Immuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 21, 2025 | finanznachrichten.deImmuneering appoints Matushansky as Chief Medical OfficerMarch 21, 2025 | markets.businessinsider.comImmuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 20, 2025 | globenewswire.comImmuneering Names Dr. Igor Matushansky as Chief Medical OfficerMarch 20, 2025 | globenewswire.comImmuneering management to meet with OppenheimerMarch 7, 2025 | markets.businessinsider.comImmuneering Slides As Insider Purchases Lose Another US$186kMarch 6, 2025 | finance.yahoo.comImmuneering and Regeneron partner on lung cancer trialFebruary 6, 2025 | msn.comImmuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)February 6, 2025 | finance.yahoo.comImmuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus LibtayoFebruary 6, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Palatin Technologies (PTN)February 6, 2025 | markets.businessinsider.comImmuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | globenewswire.comImmuneering Updates On Positive Phase 2a Results For IMM-1-104 With Modified FOLFIRINOXJanuary 14, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Sell Rating for Immuneering (IMRX)January 14, 2025 | markets.businessinsider.comImmuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic CancerJanuary 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLSN, BMEA, IMMX, and IMRX Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.44 -0.05 (-3.36%) Closing price 04:00 PM EasternExtended Trading$1.47 +0.03 (+2.08%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Imunon NASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Immix Biopharma NASDAQ:IMMX$2.33 +0.08 (+3.56%) Closing price 04:00 PM EasternExtended Trading$2.33 0.00 (-0.21%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Immuneering NASDAQ:IMRX$1.68 -0.02 (-1.18%) Closing price 04:00 PM EasternExtended Trading$1.73 +0.05 (+2.98%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
